Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: A report from the Children's Oncology Group Journal Article
| Authors: | Raney, R. B.; Anderson, J. R.; Brown, K. L.; Huh, W. W.; Maurer, H. M.; Meyer, W. H.; Parham, D. M.; Rodeberg, D. A.; Wolden, S. L.; Donaldson, S. S. |
| Article Title: | Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: A report from the Children's Oncology Group |
| Abstract: | Purpose: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997. Methods: Chart review and standard statistical procedures. Patients and Tumors: Patients were 1-18 years at diagnosis (median, 6 years). Primary tumor sites were extremity/trunk (N = 54), head/neck (N = 9), genitourinary tract (N = 7), and perineum (N = 1). Thirty patients received VA ± C with RT; 41 received VA ± C alone. RT was assigned, not randomized. Results: Fifty-four patients had Stage 1 (favorable site, any size) or Stage 2 (unfavorable site, ≤5 cm) tumors. Eight-year EFS was 90%, with 100% local control for 17 patients given RT. Eight-year EFS was 88%, with 92% local control for 37 patients without RT; P = 0.52 for EFS comparisons, 0.3 for local control comparisons. In 17 Stage 3 patients (unfavorable site, tumors >5 cm, N0), 8-year EFS was 84% with 100% local control in 13 patients given RT; 8-year EFS was only 25% and local control 50% in 4 patients without RT. Local recurrence was the most common site of first failure in non-irradiated patients. Conclusion: Patients with Stage 1-2 ALV RMS had slightly but statistically insignificantly improved local control, EFS, and OS rates when local RT was given. The need for local RT in Stage 1-2 patients deserves evaluation in a randomized study. Local control, EFS, and OS rates were significantly improved in Stage 3 patients receiving local RT. Pediatr Blood Cancer. © 2010 Wiley-Liss, Inc. |
| Keywords: | adolescent; adult; child; event free survival; preschool child; child, preschool; cancer surgery; treatment failure; major clinical study; overall survival; mortality; cancer localization; cancer recurrence; cisplatin; doxorubicin; cancer combination chemotherapy; multimodality cancer therapy; cancer radiotherapy; cancer staging; neurotoxicity; neoplasm staging; tumor volume; etoposide; cyclophosphamide; vincristine; clinical protocol; pathology; medical record review; ifosfamide; infant; dactinomycin; soft tissue sarcoma; cancer relapse; orchiectomy; urogenital system; cancer control; rhabdomyosarcoma; pediatric oncology; rhabdomyosarcoma, alveolar; perineum; trunk |
| Journal Title: | Pediatric Blood and Cancer |
| Volume: | 55 |
| Issue: | 4 |
| ISSN: | 1545-5009 |
| Publisher: | Wiley Periodicals, Inc |
| Date Published: | 2010-10-01 |
| Start Page: | 612 |
| End Page: | 616 |
| Language: | English |
| DOI: | 10.1002/pbc.22520 |
| PUBMED: | 20806360 |
| PROVIDER: | scopus |
| PMCID: | PMC3128801 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "CODEN: PBCEA" - "Source: Scopus" |
